Clinical Trial Update: A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating durvalumab in combination with extended neoadjuvant regimens for rectal cancer; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Adenocarcinoma
• Rectal Cancer
• Rectal Neoplasms

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Liz-Anne Lewsley | Conditions: Rectal Cancer, Rectal Adenocarcinoma | Phase 2 | Status: UNKNOWN